A biopharmaceutical company focused on developing and commercializing treatments for rare diseases, including a product for precocious puberty, with 18 FDA-approved drugs.
0
Orphan Designations
18
FDA Approvals
Latest: PREVDUO (2023)
0
Active Trials
1
Rare Diseases
across 2 areas
0
News (30d)
Quiet
Endo USA, Inc. is a company with 0 orphan drug designations across 1 rare disease, including 18 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| precocious puberty | SUPPRELIN LA | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio